Buscar
ADC Therapeutics SA
ADCTAñadir a la lista de seguimiento
3.430USD
-0.050-1.43%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
436.23MCap. mercado
PérdidaP/E TTM
Más Datos de ADC Therapeutics SA Compañía
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Información de ADC Therapeutics SA
Símbolo de cotizaciónADCT
Nombre de la empresaADC Therapeutics SA
Fecha de salida a bolsaMay 15, 2020
Director ejecutivoMallik (Ameet)
Número de empleados263
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 15
DirecciónBiopole
CiudadEPALINGES
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísSwitzerland
Código postal1066
Teléfono41216530200
Sitio Webhttps://adctherapeutics.com/
Símbolo de cotizaciónADCT
Fecha de salida a bolsaMay 15, 2020
Director ejecutivoMallik (Ameet)
Ejecutivos de ADC Therapeutics SA
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
2.35M
+10.02%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.58M
--
Mr. Mohamed Zaki, M.D., Ph.D.
Mr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
943.88K
+8.69%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
695.69K
+14.14%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
581.57K
+1.47%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Vice Chairman of the Board, Lead Independent Director
Non-Executive Vice Chairman of the Board, Lead Independent Director
180.15K
-0.19%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Independent Director
Non-Executive Independent Director
134.98K
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
99.40K
--
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Non-Executive Independent Director
Non-Executive Independent Director
63.01K
+12.30%
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Director
Director
40.00K
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
2.35M
+10.02%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.58M
--
Mr. Mohamed Zaki, M.D., Ph.D.
Mr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
943.88K
+8.69%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
695.69K
+14.14%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
581.57K
+1.47%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Vice Chairman of the Board, Lead Independent Director
Non-Executive Vice Chairman of the Board, Lead Independent Director
180.15K
-0.19%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de abr
Divisa: USDActualizado: lun., 6 de abr
FY2025
FY2025Q4
FY2025Q3
Por negocioUSD
Nombre
Ganancia
Proporción
Product
73.55M
90.41%
License revenue
5.00M
6.15%
Royalties
2.81M
3.45%
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Product
73.55M
90.41%
License revenue
5.00M
6.15%
Royalties
2.81M
3.45%
Estadísticas de accionistas
Actualizado: dom., 10 de may
Actualizado: dom., 10 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Redmile Group, LLC
9.91%
TCG Crossover Management, LLC
8.96%
HPWH TH AG
6.82%
Prosight Capital
6.67%
OrbiMed Advisors, LLC
4.58%
Otro
63.07%
Accionistas
Accionistas
Proporción
Redmile Group, LLC
9.91%
TCG Crossover Management, LLC
8.96%
HPWH TH AG
6.82%
Prosight Capital
6.67%
OrbiMed Advisors, LLC
4.58%
Otro
63.07%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
21.16%
Investment Advisor
18.99%
Hedge Fund
15.93%
Corporation
6.82%
Individual Investor
6.43%
Research Firm
5.02%
Private Equity
4.58%
Bank and Trust
0.71%
Pension Fund
0.12%
Otro
20.25%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
205
87.78M
69.09%
-1.77M
2025Q4
191
72.94M
63.83%
-1.48K
2025Q3
203
72.94M
76.75%
+266.41K
2025Q2
196
72.67M
64.60%
+13.50M
2025Q1
198
59.17M
80.56%
-20.65M
2024Q4
201
60.84M
78.41%
+1.63M
2024Q3
204
59.22M
80.70%
+2.20M
2024Q2
196
56.12M
64.88%
+18.35M
2024Q1
159
35.17M
75.47%
-27.30M
2023Q4
158
34.44M
76.49%
-6.23M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Redmile Group, LLC
15.67M
12.33%
--
--
Dec 31, 2025
TCG Crossover Management, LLC
11.39M
8.97%
--
--
Dec 31, 2025
HPWH TH AG
8.67M
6.82%
-1.12M
-11.42%
May 15, 2025
Prosight Capital
8.48M
6.67%
+1.01M
+13.45%
Dec 31, 2025
OrbiMed Advisors, LLC
5.82M
4.58%
-84.50K
-1.43%
Dec 31, 2025
Nantahala Capital Management, LLC
5.48M
4.31%
+3.21M
+141.60%
Dec 31, 2025
Point72 Asset Management, L.P.
5.01M
3.95%
-3.12M
-38.36%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
4.85M
3.82%
+868.36K
+21.78%
Dec 31, 2025
Oaktree Capital Management, L.P.
4.41M
3.47%
+392.78K
+9.78%
Sep 30, 2025
Eventide Asset Management, LLC
3.36M
2.65%
+3.36M
--
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Micro-Cap ETF
0.06%
SPDR S&P International Small Cap ETF
0.04%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Growth ETF
0.02%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 ETF
0.01%
Fidelity Enhanced Small Cap ETF
0%
Ver más
iShares Micro-Cap ETF
Proporción0.06%
SPDR S&P International Small Cap ETF
Proporción0.04%
iShares Biotechnology ETF
Proporción0.03%
iShares Russell 2000 Growth ETF
Proporción0.02%
ProShares UltraPro Russell2000
Proporción0.01%
ProShares Hedge Replication ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
Global X Russell 2000 ETF
Proporción0.01%
iShares Russell 2000 ETF
Proporción0.01%
Fidelity Enhanced Small Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
